Document Detail


Antigen generation and display in therapeutic antibody drug discovery - a neglected but critical player.
MedLine Citation:
PMID:  23139179     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Disease intervention by targeting a critical pathway molecule through a blocking antibody or interference by therapeutic proteins is currently en vogue. Generation of blocking antibodies or therapeutic proteins inevitably requires the production of recombinant proteins or cell-based immunogens. Thus, one could call the antigen molecule the neglected player in antibody drug discovery. The variety of methods available for making recombinant proteins or recombinant cell lines that present the target on the cell surface is extensive. These need to be addressed in conjunction with biochemical and biophysical quality criteria and the experimental application intended. Fundamentally, successful production and isolation of monoclonal antibodies requires optimized antigen preparation and presentation to the immune host. This review summarizes the most important aspects of antigen generation and display, enabling logical decision making to give rise to potent high-affinity antibodies.
Authors:
Hilmar Ebersbach; Sabine Geisse
Related Documents :
23216289 - A new human leukocyte antigen class i allele: hla-a*02:374.
23399369 - An investigation of secondary anti-d immunisation among phenotypically rhd-negative ind...
24004239 - Immunogenicity and diagnostic potential of synthetic antigenic cell surface glycans of ...
23619329 - The risk assessment study for hemolytic disease of the fetus and newborn in a universit...
1510359 - Interferon-gamma potentiates antibody-mediated demyelination in vivo.
24735599 - Development of a blocking elisa for detection of antibodies against avian hepatitis e v...
2786059 - Antigen-specific immune response impairment in the chick as influenced by dietary vitam...
11422039 - Igg, iga and ige autoantibodies against the ectodomain of desmoglein 3 in active pemphi...
9336739 - Specific activation of resting t cells against ca19-9+ tumor cells by an anti-cd3/ca19-...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-9
Journal Detail:
Title:  Biotechnology journal     Volume:  -     ISSN:  1860-7314     ISO Abbreviation:  Biotechnol J     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101265833     Medline TA:  Biotechnol J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Affiliation:
NBC/NT, Novartis Institutes for BioMedical Research, Basel, Switzerland. Hilmar.Ebersbach@novartis.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Double-effector nanoparticles: a synergistic approach to apoptotic hyperthermia.
Next Document:  Colloidal WO(3) Nanowires as a Versatile Route to Prepare a Photoanode for Solar Water Splitting.